Antiretroviral Long-Term Efficacy and Resistance of Lopinavir/Ritonavir Plus Lamivudine in HIV-1-Infected Treatment-Naïve Patients (ALTERLL): 144-Week Results of a Randomized, Open-Label, Non-Inferiority Study From Guangdong, China

Antiretroviral Long-Term Efficacy and Resistance of Lopinavir/Ritonavir Plus Lamivudine in HIV-1-Infected Treatment-Naïve Patients (ALTERLL): 144-Week Results of a Randomized, Open-Label, Non-Inferiority Study From Guangdong, China

Dual therapy with lopinavir/ritonavir (LPV/r) plus lamivudine (3TC) has been demonstrated to be non-inferior to the triple drug regimen including LPV/r plus two nucleoside reverse transcriptase inhibitors (NRTIs) in 48-week studies. However, little is known about the long-term efficacy and drug resi...

Full description

Bibliographic Details
Main Authors: Peng-Le Guo, Hao-Lan He, Xie-Jie Chen, Jin-Feng Chen, Xiao-Ting Chen, Yun Lan, Jian Wang, Pei-Shan Du, Huo-Lin Zhong, Hong Li, Cong Liu, Li-Ya Li, Feng-Yu Hu, Xiao-Ping Tang, Wei-Ping Cai, Ling-Hua Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Pharmacology
Subjects:
antiretroviral therapy
simplified regimen
randomized controlled study
lopinavir/ritonavir
inflammatory biomarker
efavirenz
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2020.569766/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2020.569766/full

Similar Items